Intravenous immunoglobulin therapy for Miller Fisher syndrome.
We analyzed clinical recovery of 92 patients with Miller Fisher syndrome who had been treated with IV immunoglobulin (IVIg; n = 28), plasmapheresis (n = 23), and no immune treatment (n = 41). IVIg slightly hastened the amelioration of ophthalmoplegia and ataxia, but the times of the disappearances of those symptoms were similar among three groups. In Miller Fisher syndrome, IVIg and plasmapheresis seem not to have influenced patients' outcomes, presumably because of good natural recovery.
Mori
Masahiro
M
Department of Neurology, Graduate School of Medicine, Chiba University, Inohana, Chuo-ku, Chiba, Japan. morim@faculty.chiba-u.jp
Kuwabara
Satoshi
S
Fukutake
Toshio
T
Hattori
Takamichi
T
D000293:Adolescent; D000328:Adult; D000368:Aged; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D019846:Miller Fisher Syndrome / Q000188:drug therapy*; D010956:Plasmapheresis / Q000379:methods
D016756:Immunoglobulins, Intravenous